Insilico Medicine

Insilico Medicine

Insilico Medicine is a drug discovery, artificial intelligence company that looks to treat cancer and age related diseases

Insilico Medicine is a drug discovery, artificial intelligence company that looks to treat cancer and age related diseases. The company was founded by Alex Zhavoronkov in 2014, in Rockville, Maryland, United States.

The company looks to extend deep learning and artificial intelligence solutions for drug and aging research. The company provides 3D molecular representations based on the wave transform for Convolution Neural Networks Molecular pharmaceutics. Insilico Medicine's drug discovery engine utilizes millions of samples and multiple data types to discover signatures of disease and to identify targets for molecules that exist or can be generated.

The company looks to launch research and development centers and research results in Taiwan. Their team consists of scientists that operate in the United States, United Kingdom, Poland, Belgium, South Korea, Taiwan, Africa, and Russia.

COVID-19

In response to the outbreak of coronavirus (COVID-19), the company has offered support to discover drugs. They have been working on research with six molecules to combat the virus. Insilico Medicine is using their AI-based drug discovery pipeline to identify drug molecules that could target 3C-like protease. 3C-like protease is a SARS-CoV-2 protein that is a target for potential drugs because it has a central role in the viral replication cycle. A portion will be tested by Insilico Medicine and the remainder of the potentially useful structures will be published on the company website and available to the public (https://insilico.com/ncov-sprint/).

Timeline

December 29, 2020
Insilico Medicine enters into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology.

September 9, 2019
Insilico Medicine raises a $37,000,000 series B round from F-Prime Capital and QiMing Venture Partners.
September 2019
Insilico Medicine raises a $37,000,000 series B round from F-Prime Capital Partners, QiMing Venture Partners, Lilly Asia Ventures, Bold Capital Partners, Baidu Ventures, Pavilion Capital, Sinovation Ventures, Eight Roads Ventures and Juvenscence.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Insilico Medicine funding round, September 2019
37,000,000
September 2019
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Alex Aliper

Employee

Alex Zhavoronkov

Founder

Alexander H. Perkins

Employee

Artem V. Artemov

Employee

Eli Mohamad

Employee

Elizabeth Galbut

Investor

Eugene Makarev

Employee

Eugeniya Cheskidova

Employee

Evgeny Putin

Employee

Ivan Ozerov

Employee

Jane Schastnaya

Employee

Ksenia Lezhnina

Employee

Marine Bozdaganyan

Employee

Matthew Gorra

Attorney

Mikhail KORZINKIN

Employee

Polina Mamoshina

Employee

Qingsong Zhu

Employee

Quentin Vanhaelen

Employee

Further reading

Title
Author
Link
Type
Date

Insilico Medicine

Web

Insilico Medicine

Web

Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Insilico Medicine

Alex Zhavoronkov

Rockville, Maryland, United States

Medical products, DNA

News

Title
Author
Date
Publisher
Description
Conor Hale
February 24, 2021
FierceBiotech
Insilico Medicine's computer networks uncovered a never-before-tried biological target linked to idiopathic pulmonary fibrosis and designed a novel molecule from scratch to potentially treat the disease--for less than $2 million and 18 months of time.
Insilico Medicine
February 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- Insilico Medicine (the "Company"), a global leader in artificial intelligence for drug discovery and biomarker development, today announced the...
February 3, 2021
WebWire
, , , , • Multi-year collaboration will use artificial intelligence (AI) and deep learning to accelerate the invention of new, more sustainable products and technologies for growers , , • Insilico Medicine is a world leader in using AI and deep learning for the faster and more efficient innovation of new active ingredients , , • Syngenta will harness the immense potential and scope of AI to develop the next generation of sustainable crop protection solutions , , , , , , Syngenta Crop Protection is...
Insilico Medicine Hong Kong Limited
December 30, 2020
www.prnewswire.com:443
/PRNewswire/ -- Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's...
Shihui Tan
November 19, 2020
TechNode
TechNode Global presented the ORIGIN Innovation Awards to outstanding startups, corporates, ecosystem enablers, and movers and shakers in Asia who are poised for growth. TechNode Global presented the ORIGIN Innovation Awards to outstanding startups, corporates, ecosystem enablers, and movers and shakers in Asia who are poised for growth.
Insilico Medicine Hong Kong Limited
November 10, 2020
www.prnewswire.com:443
/PRNewswire/ -- Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of...
Shihui Tan
November 3, 2020
TechNode
The ORIGIN Innovation Awards finalists list is up! Results will be announced on Nov. 18, 2020 during the ORIGIN Conference, so stay tuned.
Miles Goscha
October 10, 2019
TechNode
Artificial intelligence is proving useful in streamlining health-related research processes and accelerating drug development.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.